Compare Abeona Therapeutics Inc (ABEO) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Energy Select Sector SPDR Fund — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Energy Select Sector SPDR Fund trades at $61.1. Which is the better fit depends on your goals.
| ABEO | XLE | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | — |
52-Week High | $7.45 | $62.57 |
52-Week Low | $4.17 | $42.33 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
XLE trades at $60.87, up 1.13% with strong technical momentum as moving averages signal bullish conditions. The energy ETF has rallied approximately 40% over the past year, driven by elevated oil prices and geopolitical tensions in the Middle East. Recent earnings from major holdings like ExxonMobil and Chevron show strong profit growth, though valuation metrics remain undisclosed in current data.
Outlook remains positive with energy sector leadership in 2026 performance, though geopolitical risks and high volatility present challenges. The ETF's low 0.08% expense ratio and concentrated exposure to oil giants offer efficient energy market access, but dependence on Middle East stability creates significant price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
